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The Journal of Hip Preservation Surgery (JHPS) is not the
only place where work in the field of hip preservation may
be published. Although our aim is to offer the best of the
best, we continue to be fascinated by work that finds its
way into journals other than our own. There is much to
learn from it, so JHPS has selected 6 recent and topical
subjects for those who seek a summary of what is taking
place in our ever-fascinating world of hip preservation.
What you see here are the mildly edited abstracts of the
original articles to give them what JHPS hopes is a more
readable feel. If you are pushed for time, what follows
should take you no more than 10minutes to read. So here
goes . . .
RANDOMIZED CONTROLLED TRIAL (RCT)
COMPARING ARTHROSCOPIC SURGERY
AND PHYSIOTHERAPY FOR
FEMOROACETABULAR IMPINGEMENT
While the results of 2 multicentred trials (FASHIoN and
FAIT), both based in United Kingdom, have been recently
presented and we are waiting to see them in print form, we
now have the first published RCT on this topic. The
results however are not reflecting what the other published
evidence suggests.
Mansell et al. [1] aimed to determine the comparative
effectiveness of surgery and physical therapy for femoroa-
cetabular impingement syndrome in an RCT. Patients
were recruited from a large military hospital; of 104 eligible
patients, 80 elected to participate, and the majority
(91.3%) were active-duty service members. No patients
withdrew because of adverse events. The authors randomly
selected patients to undergo either arthroscopic hip sur-
gery (surgery group) or physical therapy (rehabilitation
group). Patients in the rehabilitation group began a 12-ses-
sion supervised clinic program within 3 weeks, and patients
in the surgery group were scheduled for the next available
surgery at a mean of 4months after enrollment. Patient-
reported outcomes of pain, disability and perception of
improvement over a 2-year period were collected.
The primary outcome was the Hip Outcome Score (HOS;
2 subscales: activities of daily living and sport). Secondary
measures included the International Hip Outcome Tool
(iHOT-33), Global Rating of Change (GRC) and return
to work at 2 years. The primary analysis was on patients
within their original randomization group.
Statistically significant improvements were seen in both
the groups on the HOS and iHOT-33, but the mean differ-
ence was not significant between the groups at 2 years
(HOS activities of daily living, 3.8; HOS sport, 1.8; iHOT:
33 and 6.3). The median GRC across all patients was
that they “felt about the same” (GRC¼ 0). Two patients
assigned to the surgery group did not undergo surgery, and
28 patients in the rehabilitation group ended up under-
going surgery. A sensitivity analysis of “actual surgery” to
“no surgery” did not change the outcome. Twenty (33.3%)
patients who underwent surgery and 4 (33.3%) who did
not undergo surgery were medically separated from mili-
tary service at 2 years.
The authors concluded that at 2 years there was no sig-
nificant difference between the groups, and most patients
perceived little to no change in status and one-third of mili-
tary patients were not medically fit for duty. The authors
acknowledged the limitations including a single hospital, a
single surgeon and a high rate of crossover; all of these are
up for debate until the results of the other RCTs are
published.
EFFECTS OF ARTHROSCOPY FOR
FEMOROACETABULAR IMPINGEMENT (FAI)
SYNDROME ON QUALITY OF LIFE AND
ECONOMIC OUTCOMES
One of the primary questions asked by health-care pro-
viders is the cost-effectiveness of hip arthroscopic interven-
tion in terms of quality of life. Mather et al. [2] examined
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the societal and economic impact of hip arthroscopy by
high-volume surgeons for patients with FAI syndrome
aged<50 years with noncontroversial diagnosis and indica-
tions for surgery.
The cost-effectiveness of hip arthroscopy versus nonop-
erative treatment was evaluated by calculating direct and
indirect treatment costs. Direct cost was calculated with
Current Procedural Terminology medical codes associated
with FAI treatment. Indirect cost was measured with the
patient-reported data of 102 patients who underwent arth-
roscopy and from the reimbursement records of 32 143
individuals between the ages of 16 and 79 years who had
information in a private insurance claims data set. The in-
direct economic benefits of hip arthroscopy were inferred
through regression analysis to estimate the statistical rela-
tionship between functional status and productivity. A
simulation-based approach was then used to estimate the
change in productivity associated with the change in func-
tional status observed in the treatment cohort between
baseline and follow-up. To analyze cost-effectiveness, 1-, 2-
and 3-way sensitivity analyses were performed on all varia-
bles in the model, and Monte Carlo analysis evaluated the
impact of uncertainty in the model assumptions.
Analysis of indirect costs identified a statistically signifi-
cant increase in mean aggregate productivity of $8968 after
surgery. Cost-effectiveness analysis showed a mean cumu-
lative total 10-year societal savings of $67 418 per patient
from hip arthroscopy versus nonoperative treatment. Hip
arthroscopy also conferred a gain of 2.03 quality-adjusted
life-years over this period. The mean cost for hip arthros-
copy was estimated at $23 1206 $10 279, and the mean
cost of nonoperative treatment was estimated at $91
6026 $14 675. In 99% of the trials, hip arthroscopy was
recognized as the preferred cost-effective strategy.
The work has demonstrated that FAI syndrome produ-
ces a substantial economic burden on the society which
may be reduced through the indirect cost savings and eco-
nomic benefits from hip arthroscopy.
DOES FORMAL CAPSULAR REPAIR AT THE
TIME OF HIP ARTHROSCOPY IMPROVE
CAPSULAR HEALING?
Capsular repair at the time of hip arthroscopy is a matter
of debate, and it adds time to the procedure, additional
cost in terms of equipment used, is technically challenging
and indeed it is not clear whether it improves the outcome.
In a multicentred randomized controlled collaboration be-
tween centers in New Zealand and United States, the
authors[3] have tried to evaluate the magnetic resonance
imaging (MRI) appearance of the hip capsule in patients
with femoroacetabular impingement (FAI) who underwent
simultaneous bilateral hip arthroscopy through an interpor-
tal capsulotomy with each hip randomized to undergo cap-
sular repair or not undergo such a repair.
This double-blind, randomized controlled trial included
15 patients (30 hips), with a mean age of 29.2 years, who
underwent simultaneous bilateral hip arthroscopy utilizing
a small (<3 cm) interportal capsulotomy for the treatment
of FAI. The first hip treated in each patient was intraopera-
tively randomized to undergo capsular repair or no capsu-
lar repair. The contralateral hip then received the opposite
treatment. MRI was performed at 6 and 24weeks postop-
eratively, and the scans were analyzed by 2 musculoskeletal
radiologists.
The patients and the radiologists were blinded to the
treatment performed on each hip. Capsular dimensions
were measured at the level of the healing capsulotomy site
and, for hips with a persistent defect, at locations both
proximal and distal to the defect. These values were then
analyzed at both time points to assess the rate and the ex-
tent of capsular healing.
At 6 weeks postoperatively, a continuous hip capsule
(with no apparent capsulotomy defect) was observed in 8
hips treated with capsular repair and 3 hips without such a
repair. Of the 19 hips with a discontinuous capsule at 6
weeks, 17 were available for follow-up at 24 weeks postop-
eratively; all 17 demonstrated progression to healing, with
a contiguous appearance without defects and no difference
in capsular dimensions between the treatment cohorts.
The authors concluded that arthroscopic repair of a
small interportal hip capsulotomy site yields an insignifi-
cant increase in the percentage of continuous hip capsules
seen on MRI at 6 weeks postoperatively compared with no
repair. Repaired and unrepaired capsulotomy sites pro-
gressed to healing with a contiguous appearance on MRI
by 24 weeks postoperatively.
ROLE OF PLATELET-RICH PLASMA (PRP)
in GREATER TROCHANTERIC PAIN
SYNDROME—RESULTS OF A RANDOMIZED
CONTROLLED TRIAL
Continuing with the theme of generating high-level evi-
dence, Fitzpatrick et al. [4] from Australia have looked at
the role of PRP injection in comparison with corticosteroid
for gluteal tendinopathy.
There were 228 consecutive patients referred with glu-
teal tendinopathy who were screened to enroll 80 partici-
pants; 148 were excluded for various reasons. Participants
were randomized (1:1) to receive either a blinded gluco-
corticoid or an PRP injection intratendinously under ultra-
sound guidance. A pain and functional assessment was
performed using the modified Harris hip score (mHHS) at
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0, 2, 6 and 12 weeks and the patient acceptable symptom
state (PASS) and minimal clinically important difference
(MCID) at 12 weeks.
Participants had a mean age of 60 years, a ratio of fe-
male to male of 9:1 and a mean duration of symptoms
of>14months. Pain and function measured by the mean
mHHS showed no difference at 2 weeks (corticosteroid:
66.95 versus PRP: 65.23) or 6 weeks (corticosteroid: 69.51
versus PRP: 68.79). The mean mHHS was significantly
improved (P ¼ 0.048) at 12 weeks in the PRP group
(74.05) compared with the corticosteroid group (67.13).
The proportion of participants who achieved an outcome
score of74 at 12 weeks was 17 (45.9%) of 37 in the cor-
ticosteroid group and 25 (64.1%) of 39 in the PRP group.
The proportion of participants who achieved the MCID of
more than 8 points at 12 weeks was 21 (56.7%) of 37 in
the corticosteroid group and 32 (82%) of 39 in the PRP
group (P ¼ 0.016).
The authors concluded that patients with chronic gluteal
tendinopathy>4months, diagnosed with both clinical and
radiological examinations, achieved greater clinical improve-
ment at 12weeks when treated with a single PRP injection
than those treated with a single corticosteroid injection.
INTERMEDIATE-TERM HIP SURVIVORSHIP
AND PATIENT-REPORTED OUTCOMES OF
PERIACETABULAR OSTEOTOMY: THE
WASHINGTON UNIVERSITY EXPERIENCE
The Bernese periacetabular osteotomy (PAO) has been an
alternative to arthroplasty for treating symptomatic acetab-
ular dysplasia, but there have been few studies on the
intermediate-term outcomes of this procedure. In this
study, the authors assessed intermediate-term hip survival
and patient-reported outcomes of PAO [5].
From July 1994 to August 2008, 238 hips (206 patients)
were treated with PAO. Sixty-two had a diagnosis other
than classic acetabular dysplasia, and 22 were lost to follow-
up. The remaining 154 hips (129 patients) were evaluated
at an average of 10.3 years postoperatively. Kaplan–Meier
analysis was used to assess survivorship with an end point
of total hip arthroplasty (THA). Hips were evaluated using
the University of California at Los Angeles (UCLA)
Activity Score, modified Harris hip score (mHHS) and
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) pain subscale score. A WOMAC pain
subscale score of 10 and/or an mHHS of 70 was con-
sidered to indicate a clinically symptomatic hip.
Kaplan–Meier analysis revealed a hip survival rate of
92% at 15 years postoperatively. Eight (5%) hips under-
went THA at a mean of 6.8 years. Twenty-four (16%)
additional hips were considered symptomatic based on a
WOMAC pain score of 10 and/or an mHHS of 70.
One hundred and twenty-two (79%) hips did not undergo
THA and did not meet the criteria for symptoms, and
these hips had a mean mHHS of 92.4, WOMAC pain sub-
scale score of 1.2 and UCLA Activity Score of 7.7 at a
mean of 10.1 years. A higher risk of failure was associated
with fair or poor preoperative joint congruency (odds ratio
[OR]: 8.65; P ¼ 0.034) and with a postoperative lateral
center-edge angle of >38 (OR: 8.04). A concurrent
head–neck osteochondroplasty was associated with a
decreased risk of failure (OR: 0.27; P ¼ 0.016).
This study demonstrates the durability of the Bernese
PAO. Fair or poor preoperative joint congruency and ex-
cessive postoperative femoral head coverage were found to
be predictors of failure, while concurrent head–neck osteo-
chondroplasty in patients with an inadequate range of mo-
tion after PAO was associated with a decreased risk of
failure.
PREVIOUS HIP PRESERVING SURGERY
ADVERSELY AFFECTS THE OUTCOME OF
TOTAL HIP ARTHROPLASTY (THA)
This subject has been explored in 2 recent studies; Osawa
et al. [6] from Nagoya, Japan, have looked at outcome of
THA after periacetabular osteotomy (PAO) and Konopka
et al, [7] from NY, USA, have looked at the same after hip
arthroscopic surgery.
Osawa et al. [6] performed a case–control study of 27
(29 hips) patients who underwent THA after PAO (oste-
otomy group); their mean age at surgery was 57.2 years,
and they underwent postoperative follow-up for a mean
period of 3 years.
For the control group, after matching age, sex and
Crowe classification, they included 54 (58 joints) patients
who underwent primary THA for hip dysplasia.The 2
groups demonstrated no significant difference in the pre-
operative Harris hip score, each domain of the SF-36,
JHEQ and the VAS score of hip pain and satisfaction. The
osteotomy group demonstrated significantly poor Harris
hip scores for gait and activity and JHEQ for movement at
the last follow-up. There was no significant difference in
each domain of the SF-36 and the VAS score of hip pain
and satisfaction at the last follow-up. They concluded that
previous PAO affects the quality of physical function in
patients who undergo subsequent THA.
Konopka et al. [7] in a cohort of 5091 patients who
underwent hip arthroscopy, identified 69 patients who
underwent subsequent THA (46) or hip resurfacing
arthroplasty (23). Patients were matched to patients with
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no history of hip arthroscopy. Patients who underwent
THA with history of arthroscopy had lower postoperative
hip disability and Osteoarthritis Outcome Score Pain
(82 versus 93, P ¼ 0.003), stiffness (85 versus 93, P ¼
0.01), sports and recreation (71 versus 88, P ¼ 0.003),
quality of life (65 versus 866, P < 0.0001), WOMAC Pain
(86 versus 93, P ¼ 0.03), WOMAC stiffness (80 versus 88,
P ¼ 0.05) and Short Form-12 Physical Component Scores
(48 versus 54, P ¼ 0.008). They were less likely to be “very
satisfied” after arthroplasty (71% versus 89%, P ¼ 0.0008).
It seems that both PAO and hip arthroscopy before hip
arthroplasty is associated with slightly poorer results in sev-
eral patient-reported outcomes. These results are relevant
when consenting these patients for arthroplasty.
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